King Pharmaceuticals has unveiled plans to reduce its workforce by 22 per cent in a bid to further reduce costs after the US District Court decision to invalidate patents protecting its lead product, the muscle relaxant Skelaxin (Metaxalone).
A study in the Journal of the American Medical Association (JAMA) claiming there is no evidence that brandname cardiovascular drugs are superior to their generic counterparts, despite claims to the contrary.
UK drug giant GSK is to shed 200 jobs at its manufacturing plant in Barnard Castle, County Durham to cut costs ahead of generic competition for products made at the facility, which include the anti-emetic Zofran (ondansentron).
Competition commissioner Neelie Kroes said that some drugmakers operating in the EU are deliberately stalling the introduction of generics, costing European patients around €3bn ($3.87bn) a year more to buy medicines.
The International Society of Pharmaceutical Engineers has reported
the first findings of a five-year new programme aimed at working
tackling one of the toughest problems in pharma manufacturing at
present - how to implement the new...
Switzerland-based Schweizerhall appears to have circumnavigated
patent law, with approval of its generic version of Bristol-Myers
Squibb's (BSM) and Sanofi-Aventis' Plavix (clopidogrel bisulfate)
in Germany "expected...